E-Qure Corp. reported the following material updates regarding Bioelectrical Signal Therapy device developed for the treatment of wounds via electrical stimulation, which is believed to result in accelerated wound healing by imitating the natural electrical current that occurs in injured skin on the human body. The BST Device stimulates renewed blood flow and oxygen in order to induce local cell regeneration and therefore promote wound healing. The Company has been granted with the Helsinki committee approval of Clalit Health Services Organization, Israel’s largest HMO, and the Israeli Ministry of Health (MOH) to launch a Randomized Control Study (RCT) on 60-100 patients in order to assess the efficacy of the BST Device on diabetic foot patients. The study will be performed in 3-5 sites including leading clinics and hospitals in Israel. The Company intends to enroll the first patients to the study during the next 2-3 weeks and expects the trial to be conducted for 12-18 months until completion. The Company has concluded a 35-wound, one arm clinical pilot, treating recalcitrant wounds in a leading wound clinic in Tel Aviv Israel, with 78% of the treated wounds completely healed within 20 weeks (Avg. wound duration at the base was 8 months) and an additional 16% of the treated wounds reaching wound area reduction of greater than 75%. Only 6% of the patients had no substantial positive clinical effect. The Company recently filed a provisional patent with United States Patent and Trademark Office for the purpose of protecting the main features of proprietary unique electrical healing signal BST Device. The Company’s distributor in Colombia, TekMedica SAS, has successfully concluded a clinical pilot study at the Hospital de la Samaritana in Bogota, Colombia. Starting in January 2020, Colsanitas, a leading Colombian HMO/Health insurance provider and operator of comprehensive healthcare services in Colombia and a member of the Sanitas group worldwide, will commence a clinical pilot study which is expected to be concluded by the end of the first half of 2020. If positive results are achieved, similar to those achieved in the Tel Aviv clinical trials, the Company believes that it will contribute to the penetration of the BST device treatment with Colsanitas health services in Colombia.